Mason Tenaglia offers empirical defense of coupons and copay offset programs.
The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control
Designing and deploying company copay offset programs without devaluing the brand.
An answer to your question: What does the Part D coverage gap do to drug sales?
When rebate strategies are coupled with sales force and DTC spending, it results in "margin-negative" business—that is, sales that bring in less than the marginal cost of selling, promoting, and manufacturing the drug.
The dynamic that drove the profits out of infant formula is about to be repeated—this time in pharma.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial